Pressure Monitoring Market | Analysis of Worldwide Industry Trends and Opportunities

According to research report "Pressure Monitoring Market By by Application (Respiratory, Glaucoma, Dialysis), Product (Device (Blood Pressure, Intracranial Pressure, Intraocular Pressure), Accessory), Procedure (Invasive), End User (Hospital, ASC, Diagnostic) - Global Forecast to 2020", provides a complete summary of the major drivers, restraints, challenges, opportunities, current market trends, and various strategies influencing the pressure monitoring market along with estimates and forecasts of the revenue and market share analysis.

Access Free Sample Research Copy : https://www.marketsandmarkets.com/requestsampleNew.asp?id=196787732

Pressure monitoring plays an important role in detecting the health problems of a patient. The major fluctuations of pressure in the vital areas of the body may cause various chronic and acute diseases such as diabetes, cardiac arrest, and glaucoma.

Increase in the prevalence of the above mentioned diseases and growing aging population have increased the need for pressure monitoring and control in the market.

The major factors responsible for the growth of the pressure monitoring are the rising prevalence of chronic and acute diseases, growth of aging population, new product launches, increase in the lifestyle related diseases, and technological advancements.

Due to these factors, the demand for pressure monitoring is increasing. On the other hand, lack of trained professionals, short shelf life of the device, accuracy of devices has may restrain the growth of the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=196787732

Geographically, the market is dominated by North America, followed by Europe. North America is expected to account for the largest share of the global market in 2015, with Asia having the highest growth rate during the forecast period.

Key players in the pressure monitoring market include Philips Healthcare (The Netherlands), GE Healthcare (U.K.), Welch Allyn, Inc. (U.S.), Medtronic (U.S.), and Drägerwerk AG & Co. KGaA (Germany).

Request for special pricing on bundle reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=196787732

Non Invasive Prenatal Testing Market by Product, Services, Method, Application & End-User

 According to the new market research report “Non-Invasive Prenatal Testing Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).

Browse and in-depth TOC on “Non Invasive Prenatal Testing Market”

110 - Tables

48 - Figures

150 - Pages

For Bundle Reports @ https://www.marketsandmarkets.com/RequestBundleReport.asp?id=145607690

                              
The global NIPT market is expected to reach USD 2.88 Billion by 2021 from USD 1.35 Billion in 2016, at a CAGR of 16.4% during the forecast period.

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.

To Get 10% Customization on Report @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=145607690

On the basis of product, the market is classified into consumables and instruments. The consumable segment is further divided into assay kits & reagents and disposables. The instruments segment is divided into ultrasound devices, NGS systems, PCR instruments, microarrays, and other instruments. In 2016, the consumables segment accounted for the largest share of the market. The high growth in this segment is attributed to the repeated requirements of consumables as compared to instruments in NIPT.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst@https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=145607690

The market is highly fragmented with several big and emerging players. Key market players include GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).

Opening New Avenues for Growth in Non Invasive Prenatal Testing (NIPT) Market

Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

According to the new market research report “Non-Invasive Prenatal Testing Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690



Growth prospects in Non Invasive Prenatal Testing (NIPT) Market :

The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period.

Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type). In 2018, trisomy was the largest application segment of the NIPT market.

Based on end user, the NIPT products market is classified into diagnostic laboratories and hospitals. In 2019, diagnostic laboratories formed the largest and fastest-growing end users of NIPT products.

Inquire or share your questions if any before the purchasing this report
: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=145607690

Geographically, the non-invasive prenatal testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2019, North America accounted for the largest market share, followed by Europe. On the other hand, Asia is expected to grow at the highest CAGR during the forecast period. The developing healthcare infrastructure, rising awareness programs & conferences, and rising focus of prominent players on expanding their presence in Asia are driving market growth in this region

The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)

Infectious Disease Diagnostics Market : Future of Healthcare, it is Creating Real Change in the Healthcare Industry

 The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589


According to the new market research report "Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) – Global Forecast to 2022 ", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

Global Market Segmentation:

The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service. The assays, kits, & reagents segment accounted for the largest share of the global market and is expected to register the highest CAGR during the forecast period. The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.

Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases. The hepatitis diagnostics segment accounted for the largest share of the global market in 2017. The dominant share of this segment can be attributed to the rising prevalence of hepatitis B and C, the availability of a large number of hepatitis diagnostic tests, and increasing number of HIV/Hepatitis co-infections.

The infectious disease diagnostics market is segmented into major seven technologies, namely, immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays, and other technologies. In 2017, the immunodiagnostics segment accounted for the largest share of the global market. The large share of this segment can be attributed to the increasing use of immunoassays in POC infectious disease testing, development of novel tests, rising trend of automation, and increasing awareness about health and fitness.

On the basis of end user, the global market is segmented into hospitals/clinical laboratories, reference laboratories, physician offices, academic/research institutes, and other end users. In 2017, the hospitals/clinical laboratories segment accounted for the largest share of the global market. Also, this segment is expected to grow at the highest CAGR during the forecast period due to the large number of diagnostic tests carried out in hospitals.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

What Drives the Market?

1. Increasing Global Prevalence of Infectious Diseases
2. Shift in Focus From Centralized Laboratories to Decentralized Point-Of-Care Testing
3. Growth in Funding for Research on Infectious Disease Diagnostics

Geographical Growth Analysis:

In 2017, in terms of value, North America accounted for the largest share of the global market. This large share can be attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

Some of The Major Players In Infectious Disease Diagnostics Market :

The key players in the global infectious disease diagnostics market are Abbott (US), Becton, Dickinson and Company (BD) (US), biomérieux (France), Bio-Rad (US), and Roche (Switzerland). These players focus on inorganic strategies such as acquisitions, partnerships, agreements, collaborations and as well as organic strategies such as expansions and product launches & approvals to sustain their growth in the market.

Non Invasive Prenatal Testing (NIPT) Market : Future of Healthcare, it is Creating Real Change in the Healthcare Industry

 According to the new market research report “Non-Invasive Prenatal Testing Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690

         

Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

Global Non Invasive Prenatal Testing (NIPT) Market Segmentation:

By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment is attributed to technological advancements and increasing company initiatives to develop new products.

Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type). In 2018, trisomy was the largest application segment of the NIPT market. This segment is also estimated to grow at the highest CAGR during the forecast period.

Based on end user, the NIPT products market is classified into diagnostic laboratories and hospitals. In 2019, diagnostic laboratories formed the largest and fastest-growing end users of NIPT products. This can primarily be attributed to factors such as the implementation of initiatives by diagnostic laboratories to provide safe and effective prenatal tests and rising incidence of chromosomal abnormalities.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690

What Drives the Market?

1. High Risk of Chromosomal Abnormalities With Increasing Maternal Age
2. Growing Preference for Noninvasive Techniques Over Invasive Methods
3. Improving Reimbursement Scenario for NIPT
4. Programs Focusing on Increasing the Awareness of NIPT

Geographical Growth Analysis:

Geographically, the non-invasive prenatal testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2019, North America accounted for the largest market share, followed by Europe. On the other hand, Asia is expected to grow at the highest CAGR during the forecast period. The developing healthcare infrastructure, rising awareness programs & conferences, and rising focus of prominent players on expanding their presence in Asia are driving market growth in this region

Key Players and Strategies Adopted by Them:

The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)

Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=145607690